Alternative routes of influenza vaccine delivery (Q57114644)

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Failure of influenza vaccination in the aged

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Evidence of bias in estimates of influenza vaccine effectiveness in seniors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Immunization without needles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Where adults reported receiving influenza vaccination in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Intranasal immunization against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Trivalent intranasal influenza vaccine, live

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Safety and immunogenicity of a Proteosome™-trivalent inactivated influenza vaccine, given nasally to healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

A retro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Microparticle vaccine approaches to stimulate mucosal immunisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Immunization against influenza in humans using an oral enteric-coated killed virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Epidermal delivery of protein and DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Epidermal powder immunization against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557

Role of influenza vaccine for healthy children in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.3.5.557